101. Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains
- Author
-
Jennifer A. Bartell, Robert K. Ernst, Vítor A. P. Martins dos Santos, Lauren E. Hittle, Jason A. Papin, John J. Varga, Sebastián Albertí, Xavier Mulet, Antonio Oliver, Mariette Barbier, George W. Liechti, Piotr Bielecki, Jacek Puchałka, Michael Davis, F. Heath Damron, Joanna B. Goldberg, Inmaculada Martínez-Ramos, Joshua P. Owings, and HZI-Helmholtzzentrum für Infektionsforschung
- Subjects
alelos ,tasa de mutación ,humanos ,resistencia a medicamentos ,Adaptation, Biological ,Drug Resistance ,Secondary Metabolism ,Drug resistance ,medicine.disease_cause ,Cystic fibrosis ,genómica ,Mutation Rate ,Genotype ,Gene Order ,metabolismo secundario ,Systems and Synthetic Biology ,orden génico ,biología computacional ,0303 health sciences ,Systeem en Synthetische Biologie ,Genome ,Virulence ,High-Throughput Nucleotide Sequencing ,Quorum Sensing ,Genomics ,fibrosis quística ,3. Good health ,Anti-Bacterial Agents ,Bronchiectasis ,medicine.anatomical_structure ,Phenotype ,proteínas bacterianas ,Pseudomonas aeruginosa ,pruebas de sensibilidad microbiana ,fenotipo ,antibacterianos ,Biotechnology ,Research Article ,enfermedad crónica ,Molecular Sequence Data ,Microbial Sensitivity Tests ,Biology ,Microbiology ,03 medical and health sciences ,secuenciación de nucleótidos de alto rendimiento ,Antibiotic resistance ,Bacterial Proteins ,Drug Resistance, Bacterial ,Genetics ,medicine ,Humans ,Pseudomonas Infections ,perfiles de expresión génica ,mutación ,Alleles ,030304 developmental biology ,VLAG ,Metabolic model ,genoma ,infecciones por Pseudomonas ,Lung ,030306 microbiology ,Gene Expression Profiling ,Comparative genomics ,Computational Biology ,medicine.disease ,transcriptoma ,virulencia ,bronquiectasia ,Biofilms ,Chronic Disease ,Mutation ,genotipo ,detección de quórum ,Transcriptome ,Genome, Bacterial - Abstract
Background: Pseudomonas aeruginosa is an environmentally ubiquitous Gram-negative bacterium and important opportunistic human pathogen, causing severe chronic respiratory infections in patients with underlying conditions such as cystic fibrosis (CF) or bronchiectasis. In order to identify mechanisms responsible for adaptation during bronchiectasis infections, a bronchiectasis isolate, PAHM4, was phenotypically and genotypically characterized. Results: This strain displays phenotypes that have been associated with chronic respiratory infections in CF including alginate over-production, rough lipopolysaccharide, quorum-sensing deficiency, loss of motility, decreased protease secretion, and hypermutation. Hypermutation is a key adaptation of this bacterium during the course of chronic respiratory infections and analysis indicates that PAHM4 encodes a mutated mutS gene responsible for a similar to 1,000-fold increase in mutation rate compared to wild-type laboratory strain P. aeruginosa PAO1. Antibiotic resistance profiles and sequence data indicate that this strain acquired numerous mutations associated with increased resistance levels to b-lactams, aminoglycosides, and fluoroquinolones when compared to PAO1. Sequencing of PAHM4 revealed a 6.38 Mbp genome, 5.9 % of which were unrecognized in previously reported P. aeruginosa genome sequences. Transcriptome analysis suggests a general down-regulation of virulence factors, while metabolism of amino acids and lipids is up-regulated when compared to PAO1 and metabolic modeling identified further potential differences between PAO1 and PAHM4. Conclusions: This work provides insights into the potential differential adaptation of this bacterium to the lung of patients with bronchiectasis compared to other clinical settings such as cystic fibrosis, findings that should aid the development of disease-appropriate treatment strategies for P. aeruginosa infections., This work was supported by the National Institutes of Health [J.J.V. was supported in part by T32AI055432 awarded to the University of Virginia, J.P.O. was partially supported by T32AI007046 awarded to the University of Virginia, J.A.P., J.A.B., and J.B.G. were supported in part by grant R01GM088244 awarded to J.A.P.], the Cystic Fibrosis Foundation [J.B.G., M.B., J.P.O, and M.R.D. were supported in part by GOLDBE10G0 awarded to J.B.G., F.H.D. was supported by a postdoctoral fellowship (DAMRON10F0)], the Ministerio de Economia y Competitividad and Instituto de Salud Carlos III and by the Direccio General d'Universitats, Reserca I Transferencia del Coneixement del Govern de les Illes Balears [X.M., I.M.R., S.A. and A.O were supported by SAF2008-0467, REIPI RD06/0008, RD12/0015, PRE-R-22584-2011, and PI 12/00103]. P.B. and V.A.P.M.D.S. were supported by the Helmholtz Centre for Infection Research, Germany (project: Systems Biology of Pseudomonas, number 1100187) and the FP7 projects SystemTB (# 241587) and Microme (# 222886). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- Published
- 2015